Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Advanced or Metastatic Solid Tumors 3Solid Tumors 2Sarcoma 2Carcinoma, Non-Small-Cell Lung 2Biliary Tract Neoplasms 2Solid Tumor 1Histiocytoma, Malignant Fibrous 1Endometrial Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Dermatofibrosarcoma 1Colorectal Neoplasms 1Chondrosarcoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1

Interventions

belinostat 2Gemcitabine 2Fluorouracil 2venetoclax 1toripalimab 1tazemetostat 1resiquimod 1poly ICLC 1perifosine 1pazopanib 1ivosidenib 1envafolimab 1enasidenib 1durvalumab 1drozitumab 1birinapant 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Medicare Part B 1Loperamide 1Leucovorin 1Irinotecan 1Immunotherapy 1Immune Checkpoint Inhibitors 1Imatinib Mesylate 1IPI-926 1IFL protocol 1Fentanyl 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Chondrosarcoma × envafolimab × Clear all
NCT05448820 2023-09-21

YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

Tracon Pharmaceuticals Inc.

Phase 1/2 Unknown
15 enrolled
Sarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Chondrosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡